Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Hypertension | Research

Association between hypertension and the prevalence of liver steatosis and fibrosis

Authors: Huanjie Fu, Hao Yu, Yisheng Zhao, Jinhong Chen, Zhichao Liu

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Hypertension (HTN) and non-alcoholic fatty liver disease (NAFLD) frequently coexist and share pathophysiological symptoms. Based on the liver stiffness measurement and controlled attenuation parameter obtained by performing liver transient ultrasound elastography (TUE), we determined the relationship between HTN status and the rates of liver steatosis and fibrosis in this study.

Methods

To perform this cross-sectional study, data were obtained from the National Health and Nutrition Examination Survey for 2017-March 2020 Pre-pandemic cycle. The relationship between HTN and the rates of liver steatosis and fibrosis was analyzed by constructing a multivariate logistic regression model. The VCTE was performed using a FibroScan® system (model 502, V2 Touch), and CAP was measured at ≥ 274 dB/m for liver steatosis, and the LSM result (median, ≥ 8 kPa) confirmed fibrosis. We also conducted subgroup analyses based on the age, sex, ethnicity, and body mass index (BMI) of the patients.

Results

In total, 4,705 participants were recruited, including 2,287 participants with HTN and 2,418 without HTN. After adjusting possible confounders, HTN was positively related to the liver steatosis rate (OR = 1.4, 95% CI: 1.1–1.8). Such HTN-associated prevalence was higher among males (OR = 1.6, 95% CI: 1.1–2.2), non-Hispanic African American individuals (OR = 2.1, 95% CI: 1.1–3.7), and participants with BMI ≥ 25 < 30 kg/m2 (OR = 1.7, 95% CI: 1.1–2.5). Additionally, HTN was positively associated with the fibrosis rate (OR = 2.0, 95% CI: 1.3–3.0), especially among females (OR = 2.6, 95% CI: 1.3–5.2), among individuals who were 40–59 years old (OR = 2.1, 95% CI: 1.0–4.3), 60–80 years old (OR = 2.4, 95% CI:1.3–4.6), non-Hispanic Caucasian (OR = 2.9, 95% CI: 1.5–5.6), among those with BMI ≥ 25 < 30 kg/m2 (OR = 3.0, 95% CI: 1.1–8.2), and those with BMI ≥ 30 kg/m2 (OR = 2.1, 95% CI: 1.4–3.2).

Conclusion

The results of this study revealed that HTN status was associated with higher rates of liver steatosis and fibrosis, particularly in subjects with BMI ≥ 25 kg/m2. The ethnicity of the participants also had an impact on the relationship.
Literature
1.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11–20.
2.
3.
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018 Feb;68(2):335–52.
4.
Park J, Kim G, Kim H, Lee J, Lee Y-B, Jin S-M, et al. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol. 2021 Sep;20(1):197.
5.
Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022;9:942753.CrossRefPubMedPubMedCentral
6.
Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet Lond Engl. 2021 Jun;397(10290):2212–24.
7.
Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol Off J Ger Card Soc. 2021 Jul;110(7):921–37.
8.
Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014 Sep;371(12):1131–41.
9.
Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance.Physiol Rev. 2018Oct;98(4):2133–223.
10.
Lechner K, McKenzie AL, Kränkel N, Von Schacky C, Worm N, Nixdorff U, et al. High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic Dyslipidemia, and inflammation. Metab Syndr Relat Disord. 2020 May;18(4):176–85.
11.
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular Disease in Diabetes Mellitus: atherosclerotic Cardiovascular Disease and Heart failure in type 2 diabetes Mellitus - Mechanisms, Management, and clinical considerations. Circulation. 2016 Jun;133(24):2459–502.
12.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014 May;10(5):293–302.
13.
14.
Yu EL, Golshan S, Harlow KE, Angeles JE, Durelle J, Goyal NP, et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2019 Apr;207:64–70.
15.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver Diseases. Hepatol Baltim Md. 2018 Jan;67(1):328–57.
16.
Ramírez-Vélez R, García-Hermoso A, Correa-Rodríguez M, Izquierdo M. Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease.Pediatr Res. 2022Mar;91(4):912–20.
17.
18.
Rattan P, Penrice DD, Ahn JC, Ferrer A, Patnaik M, Shah VH, et al. Inverse Association of Telomere length with Liver Disease and Mortality in the US Population. Hepatol Commun. 2022 Feb;6(2):399–410.
19.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Lond Engl. 2007 Oct;370(9596):1453–7.
20.
Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of Observational Studies in Epidemiology using mendelian randomization: the STROBE-MR Statement. JAMA. 2021 Oct;326(16):1614–21.
21.
Zhang Y, He Q, Zhang W, Xiong Y, Shen S, Yang J, et al. Non-linear Associations between visceral Adiposity Index and Cardiovascular and Cerebrovascular Diseases: results from the NHANES (1999–2018). Front Cardiovasc Med. 2022;9:908020.CrossRefPubMedPubMedCentral
22.
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019 May;156(6):1717–30.
23.
Liu X, Shen H, Chen M, Shao J. Clinical relevance of vitamins and carotenoids with liver steatosis and fibrosis detected by transient elastography in adults. Front Nutr. 2021;8:760985.CrossRefPubMedPubMedCentral
24.
Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021 Dec;S1542-3565(21)01276-3.
25.
Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021 Mar;47(2):101215.
26.
Ciardullo S, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022 Apr;34(4):365–71.
27.
Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertens Dallas Tex 1979. 2020 Aug;76(2):562–8.
28.
Ciardullo S, Monti T, Grassi G, Mancia G, Perseghin G. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population. J Hypertens. 2021 Aug;39(8):1621–7.
29.
Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020 Jan;51(2):291–304.
30.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb;482(7384):179–85.
31.
Chen J, Hu P, Wang Y, Zhu Z. Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years. BMC Endocr Disord. 2022 May;22(1):128.
32.
Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016 Aug;65(8):1109–23.
33.
Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatol Baltim Md. 2018 Jul;68(1):349–60.
34.
Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014 Jul;5(3):211–8.
35.
Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017–2018. PLoS ONE. 2021;16(6):e0252164.CrossRefPubMedPubMedCentral
36.
Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613.CrossRefPubMedPubMedCentral
37.
Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol. 2018 Jul;3(7):509–17.
38.
Abenavoli L, Pellicano R, Boccuto L. Role of genetics and metabolism in non-alcoholic fatty liver disease. Panminerva Med. 2018 Jun;60(2):41–3.
39.
Boccuto L, Abenavoli L. Genetic and Epigenetic Profile of patients with alcoholic liver disease. Ann Hepatol. 2017 Aug;16(4):490–500.
40.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019 Mar;92:98–107.
41.
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021 Apr;22(8):4156.
42.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 Jul;73(1):202–9.
43.
Zhao Y-C, Zhao G-J, Chen Z, She Z-G, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertens Dallas Tex 1979. 2020 Feb;75(2):275–84.
44.
Abenavoli L, Boccuto L, Federico A, Dallio M, Loguercio C, Di Renzo L, et al. Diet and non-alcoholic fatty liver disease: the Mediterranean Way. Int J Environ Res Public Health. 2019 Aug;16(17):E3011.
45.
Gangireddy VGR, Pilkerton C, Xiang J, Tinajero R, Ashcraft AM. Hepatic fibrosis and steatosis in metabolic syndrome. J Obes Metab Syndr. 2022 Mar;31(1):61–9.
46.
Heredia NI, Zhang X, Balakrishnan M, Hwang JP, Thrift AP. Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S. Ethn Health. 2022 Jan;1–14.
47.
S O HT, K I YS, Y O MM, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020 Apr;55(4). https://​doi.​org/​10.​1007/​s00535-019-01635-0.
48.
Chan W-K, Nik Mustapha NR, Wong GL-H, Wong VW-S, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an asian population. United Eur Gastroenterol J. 2017 Feb;5(1):76–85.
49.
Metadata
Title
Association between hypertension and the prevalence of liver steatosis and fibrosis
Authors
Huanjie Fu
Hao Yu
Yisheng Zhao
Jinhong Chen
Zhichao Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01318-1

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue

Case report

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Case report

Central pontine myelinolysis secondary to hyperglycemia

Research

Correlation of asprosin and Nrg-4 with type 2 diabetes Mellitus Complicated with Coronary Heart Disease and the Diagnostic Value

Research

An analysis of the associations of high-sensitivity C-reactive protein and uric acid with metabolic syndrome components in Korean adults by sex: a cross-sectional study using the Korea national health and nutrition examination survey 2016–2018

Research

Identification of novel circulating miRNAs biomarkers for healthy obese and lean children

Research

What is the effect of mobile phone text message reminders on medication adherence among adult type 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits